The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review

Abstract Multiple myeloma (MM) is an incurable blood cancer that primarily affects older adults. Several frailty tools have been developed to address the heterogeneity of aging in this population. Uptake of these measures has been variable, leading to a gap in knowledge regarding the proportion of e...

Full description

Bibliographic Details
Main Authors:	Hira Mian, Arleigh McCurdy, Smith Giri, Shakira Grant, Bram Rochwerg, Erica Winks, Ashley E. Rosko, Monika Engelhardt, Charlotte Pawlyn, Gordon Cook, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M. Wildes
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-01-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00779-2

Similar Items

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
by: Owais Mian, et al.
Published: (2023-01-01)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
by: Arleigh McCurdy, et al.
Published: (2023-07-01)

Age and aging in blood disorders: multiple myeloma
by: Sonja Zweegman, et al.
Published: (2014-07-01)

The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences
by: Cheryl Pritlove, et al.
Published: (2021-07-01)

MRD negativity: considerations for older adults with multiple myeloma
by: Hira Mian, et al.
Published: (2023-11-01)

The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience
by: Amarilis Figueiredo, et al.
Published: (2019-10-01)

Multiple myeloma
by: Sonja Zweegman, (Coordinating Author)
Published: (2019-06-01)

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial
by: Arleigh McCurdy, et al.
Published: (2024-09-01)

Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study
by: Hira S Mian, et al.
Published: (2020-12-01)

Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study
by: Hira Mian, et al.
Published: (2023-05-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)

SAFETY OF DARATUMUMAB IN FRAIL PATIENTS WITH MULTIPLE MYELOMA
by: TX Carneiro, et al.
Published: (2023-10-01)

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
by: Hira Mian, et al.
Published: (2023-02-01)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
by: Arleigh McCurdy, et al.
Published: (2023-07-01)

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
by: Arleigh McCurdy, et al.
Published: (2023-08-01)

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
by: Evangelos Terpos, et al.
Published: (2015-10-01)

Molecular profiling in myeloma
by: Charlotte Pawlyn, et al.
Published: (2018-06-01)

Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report
by: Manar Alabdulbaqi, et al.
Published: (2020-07-01)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-11-01)

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
by: Yuichi Horigome, et al.
Published: (2024-03-01)

Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study
by: Alissa Visram, et al.
Published: (2024-08-01)

Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?
by: Monika Engelhardt, et al.
Published: (2019-11-01)

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
by: Julie Côté, et al.
Published: (2023-09-01)

Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database
by: Rayan Kaedbey, et al.
Published: (2024-06-01)

Frail Multiple Myeloma Patients Deserve More Than Just a Score
by: Hannah Louise Miller, et al.
Published: (2023-02-01)

HOW TO TREAT UNFIT AND FRAIL PATIENTS
by: Gordon Cook
Published: (2022-04-01)

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study
by: Mégane Tanguay, et al.
Published: (2024-11-01)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
by: Hira Mian, et al.
Published: (2022-02-01)

Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?
by: Hira Mian, et al.
Published: (2024-01-01)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
by: Sarah A. Bird, et al.
Published: (2020-05-01)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
by: Esther A. Zaal, et al.
Published: (2017-08-01)

Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment?
by: Salomon Manier, et al.
Published: (2024-04-01)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
by: Sara Bringhen, et al.
Published: (2018-09-01)

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
by: Jo Caers, et al.
Published: (2018-11-01)

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
by: Schoenbeck KL, et al.
Published: (2020-05-01)

Gender disparities in multiple myeloma publications
by: Aala Dweik, et al.
Published: (2022-08-01)

Morphology of paraspinal muscles in frail and non-frail older adults evaluated through FRAIL scale
by: Rufeng Huang, et al.
Published: (2023-01-01)

The Fragility of Dissent!: Mediated Resistance at the Gleneagles G8 Summit and the Impact of the 7/7 London Bombings
by: Patrick McCurdy
Published: (2011-06-01)

ACHIEVING DIVERSITY THROUGH ONLINE INTER-INSTITUTIONAL COLLABORATIONS
by: Shari McCurdy
Published: (2019-03-01)